• news.cision.com/
  • Cline/
  • Cline Scientific initiates collaboration with global biopharmaceutical company with the aim of uncovering core mechanisms of vascular disease

Cline Scientific initiates collaboration with global biopharmaceutical company with the aim of uncovering core mechanisms of vascular disease

Report this content

Cline Scientific has entered into a collaboration with AstraZeneca to utilise Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon 2020 funded project which aims to uncover core mechanisms of vascular anomalies and to leverage this information for establishing new therapeutics for vascular disease. The project consists of 14 individual research projects across seven academic labs and two industry partners.

Vascular anomalies are defects of the vascular system that can be either with blood or lymph vessels. Many vascular anomalies are congenial and inherited, but they can also be brought on by events such as trauma and pregnancy. Vascular anomalies can be malformations or tumours, which range from harmless to life-threatening.

As part of one of the V.A Cure projects, a Ph.D. student at AstraZeneca will use Cline’s gradient surface technology and methods in the development of protocols with the aim of differentiating iPS cells into cell types which are relevant for vascular anomalies. The project also aims to transform these stem cells to form vascular tissue and create a homogenous cell line for vascular anomalies which has not previously been possible.  Should the project prove successful, the protocols and cell lines have the potential to be used in other studies and for the generation of novel treatments.

“This project represents an exciting possibility for Cline’s surface technology to be applied to a different type of cell and disease area. The use of Cline’s gradient surfaces in the V.A Cure project serves to further validate the use of nanogradient surfaces in cellular research and therapy development.”  says Patrik Sundh, CEO, Cline Scientific.

Cline gradient surfaces and stem cell differentiation method have already been successful to drive the differentiation of iPS cells into human cartilage. This achievement lead to the development of Cline’s regenerative medicine therapy project, StemCART.

Cline Scientific is a member of AstraZeneca’s BioVentureHub in Gothenburg, Sweden.

For more information about V.A Cure, follow the link to https://vacure.eu/.

This disclosure contains information that Cline is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25 January 2021.

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55

Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase


Documents & Links